Company Description
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 382 |
| CEO | Mark Baum |
Contact Details
Address: 1A Burton Hills Boulevard, Suite 200 Nashville, Tennessee 37215 United States | |
| Phone | 615 733 4730 |
| Website | harrow.com |
Stock Details
| Ticker Symbol | HROW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | 415858109 |
| ISIN Number | US4158581094 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Saharek MBA | President and Chief Executive Officer of Harrow's ImprimisRx Division |
| Mark L. Baum J.D. | Chief Executive Officer and Chairman of the Board |
| Andrew R. Boll C.F.A., C.M.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Amir H. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer |
| Michael D. Biega | Vice President of Investor Relations and Communications |
| Brett A. Burrell | Vice President of Legal and Compliance |
| Kim Barratt | Chief Talent Officer |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs and Pharmacovigilance |
| Greg DiPasquale | Senior Vice President and Head of Commercial |
| Dr. Prashanth S. Annavajjhala | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jun 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 9, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |